1,3-dipropyl-8-cyclopentylxanthine has been researched along with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lau, YS; Mouradian, MM | 1 |
| Beilstein, M; Castagnoli, K; Castagnoli, N; Chen, JF; Petzer, JP; Schwarzschild, MA; Sonsalla, PK; Staal, R; Xu, K; Xu, YH | 1 |
2 other study(ies) available for 1,3-dipropyl-8-cyclopentylxanthine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
| Article | Year |
|---|---|
Protection against acute MPTP-induced dopamine depletion in mice by adenosine A1 agonist.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Adenosine; Animals; Corpus Striatum; Dopamine; Kinetics; Male; Mice; Mice, Inbred C57BL; Receptors, Purinergic; Time Factors; Xanthines | 1993 |
Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Caffeine; Catechols; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Immunity, Innate; Injections, Intraperitoneal; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Neuroprotective Agents; Parkinsonian Disorders; Purinergic P1 Receptor Antagonists; Purines; Pyrimidines; Receptor, Adenosine A2A; Receptors, Purinergic P1; Theobromine; Triazoles; Xanthines | 2001 |